Jonathan Waltuck and Jill P. Buyon
1 April 1994 | Volume 120 Issue 7 | Pages 544-551
To determine the initial clinical status and thelong-term outcome of mothers and their children with autoantibody-associatedcongenital heart block.Objective:
Dynamic, longitudinal cohort study.Design:
55 children with isolated congenital heart block,their 52 mothers, and 5 other women currently carrying fetuseswith congenital heart block. All maternal sera contained antibodiesto SSA/Ro alone or to both SSA/Ro and SSB/La.Patients:
Clinical information obtained from mailed questionnaires,telephone interviews, primary physicians, and chart reviews.Measurements:
When congenital heart block was identified in thechildren, 23 women were asymptomatic, 15 had systemic lupuserythematosus, 8 had the Sjogren syndrome, and 11 had an undifferentiatedautoimmune syndrome. Follow-up ranged from 1 week to 20 years(median, 3.7 years). Eleven (48%) of the 23 initially asymptomaticmothers developed symptoms of a rheumatic disease (0.15 statuschanges/patient-year of follow-up; 6 [26%] developed an undifferentiatedautoimmune syndrome, 2 (9%) developed the Sjogren syndrome,and 3 (13%) developed systemic lupus erythematosus. One motherwith the Sjogren syndrome progressed to systemic lupus erythematosus.Four (16%) of 25 subsequent pregnancies in 22 women were complicatedby heart block. Seventeen affected children died, 12 within1 month of birth. Pacemakers were implanted in 37 (67%) of the55 children, 27 within 3 months after birth.Results:
The development of rheumatic disease in asymptomaticmothers identified by the birth of a child with congenital heartblock is common but not universal. The risk for congenital heartblock in subsequent pregnancies is low. One third of the childrenwith autoantibody-associated congenital heart block die in theearly neonatal period and, of those who survive, most requirepacemakers.Conclusion:
Author and Article Information
From the Hospital for Joint Diseases, New York University School of Medicine, New York, New York. Jill P. Buyon, MD, Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003. The authors thank the following physicians who generously provided serum samples and clinical histories on their patients: Drs. Carol Aitcheson, Frank Arnett, Balu Athreya, Laxmi Baxi, Seth Berney, Joshua Copel, Patricia Fraser, Richard Furie, Patricia Hopkins, Angela Horsfall, Paul Howard, Leslie Kahl, Jeffrey Korotkin, Bernhard Lang, Thomas Lehman, Michael Lockshin, Janice Lysiak, Joseph Miller, Renee Norberg, Ann Parke, Michelle Petri, Lisa Rider, Lisa Sammaritano, Philip Saul, Sandra Sessoms, Earl Silverman, Eng Tan, Patience White, Robert Winchester, and Samuel Zwillich. In part by a grant from the Arthritis Foundation, New York Affiliate (Dr. Buyon).
Requests for Reprints:
Grant Support:
This article has been cited by other articles:
A. C. Glatz, J. W. Gaynor, L. A. Rhodes, J. Rychik, R. E. Tanel, V. L. Vetter, J. R. Kaltman, S. C. Nicolson, L. Montenegro, and M. J. Shah J. Thorac. Cardiovasc. Surg., September 1, 2008; 136(3): 767 - 773.
Outcome of high-risk neonates with congenital complete heart block paced in the first 24 hours after birth
M. E. Mangoni and J. Nargeot Physiol Rev, July 1, 2008; 88(3): 919 - 982.
Genesis and Regulation of the Heart Automaticity
J.P. Buyon and R.M. Clancy Lupus, February 1, 2008; 17(2): 86 - 90.
Dying right to live longer: positing apoptosis as a link between maternal autoantibodies and congenital heart block
[Abstract] [PDF]
D. M. Friedman, M. Y. Kim, J. A. Copel, C. Davis, C. K.L. Phoon, J. S. Glickstein, J. P. Buyon, and for the PRIDE Investigators Circulation, January 29, 2008; 117(4): 485 - 493.
Utility of Cardiac Monitoring in Fetuses at Risk for Congenital Heart Block: The PR Interval and Dexamethasone Evaluation (PRIDE) Prospective Study
P.A. Gordon Lupus, August 1, 2007; 16(8): 642 - 646.
Review: Congenital heart block: clinical features and therapeutic approaches
A. G. Tzioufas and H. M. Moutsopoulos Rheumatology, August 1, 2007; 46(8): 1221 - 1222.
Predicting autoimmune congenital heart block: is it feasible and how?
[Full Text] [PDF]
L Strandberg, S Salomonsson, K Bremme, S-E Sonesson, and M Wahren-Herlenius Lupus, June 1, 2006; 15(6): 346 - 353.
Ro52, Ro60 and La IgG autoantibody levels and Ro52 IgG subclass profiles longitudinally throughout pregnancy in congenital heart block risk pregnancies
N Costedoat-Chalumeau, S Georgin-Lavialle, Z Amoura, and J-C Piette Lupus, September 1, 2005; 14(9): 660 - 664.
Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block
Y. Qu, G. Baroudi, Y. Yue, and M. Boutjdir Circulation, June 14, 2005; 111(23): 3034 - 3041.
Novel Molecular Mechanism Involving {alpha}1D (Cav1.3) L-Type Calcium Channel in Autoimmune-Associated Sinus Bradycardia
G E Katsifis and A G Tzioufas Lupus, September 1, 2004; 13(9): 673 - 678.
Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide
J P Buyon, A Rupel, and R M Clancy Lupus, September 1, 2004; 13(9): 705 - 712.
Neonatal lupus syndromes
K. Hu, Y. Qu, Y. Yue, and M. Boutjdir Circ. Res., March 5, 2004; 94 (4): e32 - e38.
Functional Basis of Sinus Bradycardia in Congenital Heart Block
N Costedoat-Chalumeau, Z Amoura, D Le Thi Hong, B Wechsler, D Vauthier, P Ghillani, T Papo, O Fain, L Musset, and J-C Piette Ann Rheum Dis, October 1, 2003; 62(10): 1010 - 1012.
Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block
[Abstract] [Full Text]
R. M. Clancy, C. B. Backer, X. Yin, R. P. Kapur, Y. Molad, and J. P. Buyon J. Immunol., September 15, 2003; 171(6): 3253 - 3261.
Cytokine Polymorphisms and Histologic Expression in Autopsy Studies: Contribution of TNF-{alpha} and TGF-{beta}1 to the Pathogenesis of Autoimmune-Associated Congenital Heart Block
A Brucato, A Jonzon, D Friedman, L D Allan, G Vignati, M Gasparini, J I Stein, S Montella, M Michaelsson, and J Buyon Lupus, June 1, 2003; 12(6): 427 - 435.
Proposal for a new definition of congenital complete atrioventricular block
L. E. Nield, E. D. Silverman, J. F. Smallhorn, G. P. Taylor, J. Brendan, M. Mullen, L. N. Benson, and L. K. Hornberger J. Am. Coll. Cardiol., August 21, 2002; 40(4): 796 - 802.
Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block
E Rosenthal Lupus, March 1, 2002; 11(3): 135 - 136.
Spectrum of conduction abnormalities associated with maternal anti-Ro antibodies
[PDF]
E. T. Jaeggi, R. M. Hamilton, E. D. Silverman, S. A. Zamora, and L. K. Hornberger J. Am. Coll. Cardiol., January 2, 2002; 39(1): 130 - 137.
Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block: A single institution's experience of 30 years
G.-Q. XIAO, Y. QU, K. HU, and M. BOUTJDIR FASEB J, July 1, 2001; 15(9): 1539 - 1545.
Down-regulation of L-type calcium channel in pups born to 52 kDa SSA/Ro immunized rabbits
B Maisch and A.D Ristic Eur. Heart J., May 2, 2001; 22(10): 813 - 824.
Immunological basis of the cardiac conduction and rhythm disorders
M. Restivo, D. O. Kozhevnikov, and M. Boutjdir Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1889 - H1895.
Optical mapping of activation patterns in an animal model of congenital heart block
[Abstract] [Full Text] [PDF]
G.-Q. Xiao, K. Hu, and M. Boutjdir Circulation, March 20, 2001; 103(11): 1599 - 1604.
Direct Inhibition of Expressed Cardiac L- and T-Type Calcium Channels by IgG From Mothers Whose Children Have Congenital Heart Block